Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The study will compare the pharmacokinetics (PK), safety and tolerability of long-term
infusion of lyophilized landiolol (LDLL600) against esmolol (Brevibloc) by measurement of
blood concentrations of landiolol, esmolol and their metabolites, and by monitoring systemic
cardiovascular and local tolerability, blood pressure (BP), ECG including heart rate (HR) and
adverse events (AEs).